Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells

Molecular Medicine Reports

Volumn 10, Issue 3, 2014, Pages 1205-1214

  Yang, Weihan ^a   Wang, Yu ^a   Pu, Qiang ^a   Ye, Sujuan ^a   Ma, Qingping ^a   Ren, Jiang ^a   Zhong, Guoxing ^a   Liu, Lunxu ^a   Zhu, Wen ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

A549 lung adenocarcinoma cells; Complement; Initiation and progression; Molecular mechanism; SLC34A2; Viability and invasion

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; DUAL SPECIFICITY PHOSPHATASE 6; PDZK1 INTERACTING PROTEIN 1; PHOSPHATE; PROTEIN; SELENIUM BINDING PROTEIN; SELENIUM BINDING PROTEIN 1; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG; DUSP6 PROTEIN, HUMAN; MEMBRANE PROTEIN; PDZK1IP1 PROTEIN, HUMAN; SELENBP1 PROTEIN, HUMAN; SLC34A2 PROTEIN, HUMAN; SODIUM PHOSPHATE COTRANSPORTER 2B; THIOREDOXIN;

A549 CELL LINE; ABSORPTION; ARTICLE; CANCER CELL LINE; CELL INVASION; CELL VIABILITY; COLONY FORMATION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GROWTH CURVE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SLC34A2 GENE; STABLE TRANSFECTION; TUMOR SUPPRESSOR GENE; UPREGULATION; ADENOCARCINOMA; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LUNG ALVEOLUS CELL; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; COMPLEMENT C3; COMPLEMENT C4B; DOWN-REGULATION; DUAL SPECIFICITY PHOSPHATASE 6; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PNEUMOCYTES; SELENIUM-BINDING PROTEINS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIB; THIOREDOXINS; UP-REGULATION;

EID: 84905453934     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2376     Document Type: Article

References (60)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Murer H, Forster I and Biber J: The sodium phosphate cotransporter family SLC34. Pfugers Arch 447: 763-767, 2004. (Pubitemid 38241464)
3. Zheng X, Kammerer CM, Cox LA, Morrison A, Turner ST and Ferrell RE: Association of SLC34A2 variation and sodium-lithium countertransport activity in humans and baboons. Am J Hypertens 22: 288-293, 2009.
4. Lituiev DS and Kiyamova RG: Mutations in the gene of human type IIb sodium-phosphate cotransporter SLC34A2. Biopolym Cell 26: 13-22, 2010.
5. Tenenhouse HS: Phosphate transport: Molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 103: 572-577, 2007.
6. Xu H, Bai L, Collins JF and Ghishan FK: Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). Genomics 62: 281-284, 1999. (Pubitemid 30053944)
7. Corut A, Senyigit A, Ugur S, Altin S, Ozcelik U, Calisir H, Yildirim Z, Gocmen A and Tolun A: Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 79: 650-656, 2006. (Pubitemid 44452742)
8. Vachon L, Fareau GE, Wilson MG and Chan LS: Testicular microlithiasis in patients with Down syndrome. J Pediatr 149: 233-236, 2006. (Pubitemid 44128551)
9. Hernando N, Sheikh S, Karim-Jimenez Z, Galliker H, Forgo J and Biber J: Asymmetrical targeting of type II Na-P(i) cotransporters in renal and intestinal epithelial cell lines. Am J Physiol Renal Physiol 278: F361-F368, 2000. (Pubitemid 30163234)
10. Cerri MF, Rezende LC, Paes FM, Silva IV and Rangel LBA: The cotransporter NaPi-IIb: characteristics, regulation and its role in carcinogenesis. Applied Cancer Res 30: 197-203, 2010.
11. Shibasaki Y, Etoh N and Hayasaka M: Targeted deletion of the tybe IIb Na+ dependent Pi-co-transporter, NaPi-IIb, results in early embryonic lethality. Biochem Biophys Res Commun 381: 482-486, 2009.
12. Kopantzev EP, Monastyrskaya GS, Vinogradova TV, et al: Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. Lung Cancer 62: 23-34, 2008.
13. el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR and Baylin SB: High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA 88: 3470-3474, 1991. (Pubitemid 21916643)
14. Lengauer C, Kinzler KW and Vogelstein B: DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 94: 2545-2550, 1997. (Pubitemid 27136912)
15. Liu H, Kho AT, Kohane IS and Sun Y: Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med 3: e232, 2006.
16. Ramirez MI, Pollack L, Millien G, Cao YX, Hinds A and Williams MC: The alpha-isoform of caveolin-1 is a marker of vasculogenesis in early lung development. J Histochem Cytochem 50: 33-42, 2002. (Pubitemid 34074620)
17. Hnasko R and Ben-Jonathan N: Developmental regulation of PV-1 in rat lung: association with the nuclear envelope and limited colocalization with Cav-1. Am J Physiol Lung Cell Mol Physiol 288: L275-L284, 2005. (Pubitemid 40105366)
18. Wiliams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494-C506, 2005.
19. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD, Shay JW, Gazdar AF and Minna JD: Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 64: 4277-4285, 2004. (Pubitemid 38802434)
20. Bélanger MM, Gaudreau M, Roussel E and Couet J: Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3: 954-959, 2004. (Pubitemid 41351018)
21. Traebert M: Expression of type II Na-P(i) cotransporterin alveolar type II cells. Am J Physiol 277: L868-L873, 1999.
22. Griffiths MJ, Bonnet D and Janes SM: Stem cells of the alveolar epithelium. Lancet 366: 249-260, 2005. (Pubitemid 40981054)
23. Kinnard WV, Tuder R, Papst P and Fisher JH: Regulation of alveolar type II cell differentiation and proliferation in adult rat lung explants. Am J Respir Cell Mol Biol 11: 416-425, 1994.
24. Ten Have-Opbroek AA, Benfield JR, Hammond WG and Dijkman JH: Alveolar stem cells in canine bronchial carcinogenesis. Cancer Lett 101: 211-217, 1996. (Pubitemid 26082276)
25. Ten Have-Opbroek AA, Benfield JR, van Krieken JH and Dijkman JH: The alveolar type II cell is a pluripotential stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas. Histol Histopathol 12: 319-336, 1997. (Pubitemid 27240303)
26. Kitinya JN, Sueishi K, Tanaka K and Katsuda Y: Immunoreactivity of surfactant-apoprotein adenocarcinomas, large cell and small cell carcinomas of the lung. Acta Pathol Jpn 36: 1271-1278, 1986. (Pubitemid 17209579)
27. Gazdar FA, Linnoila R, Kurita Y, et al: Peripheral airway cell differentiation in human lung cancer. Cancer Res 50: 5481-5487, 1990. (Pubitemid 20303008)
28. Holm BA, Matalon S, Finkelstein JN and Notter RH: Type II pneumocyte changes during hyperoxic lung injury and recovery. J Appl Physiol (1985) 65: 2672-2678, 1988.
29. Kim CF, Jackson EL, Woolfenden AE, et al: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835, 2005. (Pubitemid 40806415)
30. Xu CX, Jin H, Chung YS, et al: Low dietary inorganic phosphate affects the lung growth of developing mice. J Vet Sci 10: 105-113, 2009.
31. Tsao MS, Zhu H and Viallet J: Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells. Exp Cell Res 223: 268-273, 1996. (Pubitemid 26089083)
32. Lieber M, Smith B, Szakal A, Nelson-Rees W and Todaro G: A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 17: 62-70, 1976.
33. Xu Q, Lu A, Xiao G, et al: Transcriptional profiling of midgut immunity response and degeneration in the wandering silkworm, Bombyx mori. Plos one 7: e43769, 2012.
34. Hill LD, Sun L, Leuschen MP and Zach TL: C3 synthesis by A549 alveolar epithelial cells is increased by interferon-γ and dexamethasone. Immunology 79: 236-240, 1993. (Pubitemid 23172218)
35. Neal C, Neal M and Wickham H: Phosphate measurement in natural waters: two examples of analytical problems associated with silica interference using phosphomolybdic acid methodologies. Sci Total Environ 252: 511-512, 2000.
36. Gałeza M, Zebracka J, Szpak-Ulczok S, et al: Expression of selected genes involved in transport of ions in papillary thyroid carcinoma. Endokrynol Pol 57: 26-31, 2006 (In Polish).
37. Blanchard A, Shiu R, Booth S, et al: Gene expression profiling of early involuting mammary gland reveals novel genes potentially relevant to human breast cancer. Front Biosci 12: 2221-2232, 2007.
38. Yin BW, Kiyamova R, Chua R, Caballero OL, et al: Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun 8: 3, 2008.
39. Cuzin M: DNA chips: a new tool for genetic analysis and diagnostics. Transfus Clin Biol 8: 291-296, 2001.
40. Strunk RC, Eidlen DM and Mason RJ: Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 81: 1419-1426, 1988.
41. Niculescu F, Rus HG, Retegan M and Vlaicu R: Persistent complement activation on tumor cells in breast cancer. Am J Pathol 140: 1039-1043, 1992.
42. Magyarlaki T, Mosolits S, Baranyay F and Buzogany I: Immunohistochemistry of complement response on human renal cell carcinoma biopsies. Tumori 82: 473-479, 1996. (Pubitemid 27013332)
43. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446, 2000. (Pubitemid 30208162)
44. Kierszenbaum F and Budzko DB: Cytotoxic effects of normal sera on lymphoid cells. I. Antibody-independent killing of heterologous thymocytes by guinea pig, rabbit, and human sera: Role of the alternative pathway of complement activation. Cell Immunol 29: 137-146, 1977. (Pubitemid 8070917)
45. Rothman BL, Despins AW and Kreutzer DL: Cytokine regulation of C3 and C5 production by the human type II pneumocyte cell line, A549. J Immunol 145: 592-598, 1990. (Pubitemid 20252367)
46. Rothman BL, Merrow M, Despins A, Kennedy T and Kreutzer DL: Effect of lipopolysaccharide on C3 and C5 production by human lung cells. J Immunol 143: 196-202, 1989. (Pubitemid 19174220)
47. Duerst RE, Ryan DH and Frantz CN: Variables affecting the killing of cultured human neuroblastoma cells with monoclonal antibody and complement. Cancer Res 46: 3420-3425, 1986. (Pubitemid 16096883)
48. Jima DD, Shaha RN, Orcutta TM: Enhanced transcription of complement and coagulation genes in the absence of adaptive immunity. Mol Immunol 46: 1505-1516, 2009.
49. Hickman-Davis JM, Fang FC and Nathan C: Lung surfactant and reactive oxygen-nitrogen species: antimicrobial activity and host-pathogen interactions. Am J Physiol Lung Cell Mol Physiol 281: L517-L523, 2001.
50. Malmsten M, Lassen B, James MV and Nilsson UR: Adsorption of complement proteins C3 and C1q. J Colloid Interface Sci 178: 123-134, 1996. (Pubitemid 26166509)
51. Mold C: Effect of membrane phospholipids on activation of the alternative complement pathway. J Immunol 143: 1663-1668, 1989.
52. Takeda E, Yamamoto H, Nashiki K, Sato T, Arai H and Taketani Y: Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 8: 191-200, 2004. (Pubitemid 44145508)
53. Furukawa T, Sunamura M, Motoi F, Matsuno S and Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807-1815, 2003. (Pubitemid 36613039)
54. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD and Halmos B: Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31: 577-586, 2010.
55. Li T, Yang W and Li M: Expression of selenium binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52: 1289-1299, 2008.
56. Huang KC, Park DC, Ng SK et al: Selenium binding protein 1 in ovarian cancer. Int J Cancer 118: 2433-2440, 2006.
57. Chen G, Wang H and Miller CT: Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202: 321-329, 2004. (Pubitemid 38325241)
58. Yang M and Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58: 3150-3153, 1998. (Pubitemid 28335099)
59. Parikh H, Carlsson E, Chutkow WA and Johansson LE: TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4: e158, 2007.
60. Capuano P, Bacic D and Stange G: Expression and regulation of the renal Na/phosphate cotransporter NaPi-IIa in a mouse model deficient for the PDZ protein PDZK1. Pflugers Arch 449: 392-402, 2005.